Anavex Life Sciences Corp (AVXL)

[nidan7500]

https://www.accessdata.fda.gov/cdrh_docs/pdf14/K141316.pdf. 510K for Cognision device class II, SW device FDA licensed site.
Patent application June 2017 for AVXL w/Cognision technology officer Ceocchi as inventor.
. http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180360796%22.PGNR.&OS=DN/20180360796&RS=DN/20180360796
ref to a Journal publication (Alzh. & dementia).

Many moving parts w/dates suggesting a bigger story. maybe this gets at part of what biostockclub was referring to about new information coming.
My read(which may be wrong) is that the patent application and the coinventor relation w/cognision suggests a partnership of some kind. The patent data can be read as a report of a field of testing information which appears to show effective treatment of AD patients. I am unclear if this should be read as literal results and rationale for the claim or as hypotheticals. Trying to connect the dots. Suggest reading every line in patent app., it is describing a process for treatment, IMO. The product is the process used and the pharma/AI technology.

The most interesting part to me suggest that development of a diagnostic and treatment service for AD patients service seems to be described. The patent is actually about a process for AD diagnostic using Cognision AI S/W-H/W together with AD A2-73 treatment process. Over time (days/weeks) patients are tested, measured, dosed, measured, and so forth until an optimal dose is determined using Biomarker information generated during treatment cycle from AI based cognision system. Will keep looking for links but it appears this may have been going on for a while. Thoughts??